Appropriate Use of Laboratory Tests
09-18-2026 | Biologie médicale et génomique, Usage optimal
18 septembre 2026 - Dernière mise à jour : Fer sérique, Urée sérique, et T4L
An update of the Appropriate Use of 14 Biomedical Laboratory Tests document (INESSS, 2014) is ongoing. Please see the information below.
In Canada, biomedical laboratory tests account for approximately 5% of total healthcare expenditures, and between 20% and 40% of tests done may be of low clinical value or inappropriate.
Inappropriate use of biomedical laboratory tests exerts financial pressure on the healthcare system, generates waste, unnecessarily increases the workload of healthcare professionals and laboratory personnel, and may result in more harm than benefit for patients. Furthermore, inappropriate utilization of tests can limit access to relevant testing and prolong turnaround times for results required in clinical decision-making. These issues highlight the importance of selecting tests that are necessary and appropriate to the clinical context.
These publications are part of a series of projects aimed at updating a practical tool covering 14 biomedical laboratory tests commonly ordered in clinical practice. The objective is to promote the appropriate use of laboratory testing by reducing low-value test requests and harmonizing practices across Québec. Guidance sheets are provided to support healthcare professionals in applying best practices, along with reports presenting implementation strategies and recommendations to facilitate uptake and integration into practice.
Biomedical Laboratory Tests:
- Serum Iron (published)
- Serum Urea (published)
- Free Thyroxine (published)
- Aspartate Aminotransferase (AST) (published)
- Direct Bilirubin (published)
- Serum Protein Electrophoresis (published)
- Serum (1-3)-β-D-Glucan (published)
- Serum Folate (published)
- In Vivo Bleeding Time (published)
- Vitamin B12 (published)
- 25-hydroxy (25-OH) Vitamin D (published)
- Erythrocyte Sedimentation Rate (published)
- Serum Amylase (forthcoming)
- Creatine Kinase-MB (forthcoming)
- Serum Ferritin (forthcoming)
- Hereditary Hemochromatosis Type I; HFE (C282Y, H63D) (forthcoming)
- Lactate Dehydrogenase (forthcoming)
Nous avons besoin de votre opinion !
Sondage portant sur les Outils - Utilisation judicieuse des analyses biomédicales :
- Fer sérique
- Urée sérique
- T4L
- Électrophorèse des protéines sériques
- Dosage des folates sériques
- Dosage de la vitamine B12
- Test de la vitesse de sédimentation érythrocytaire
- Aspartate aminotransférase (AST) pour l'investigation d'une atteinte hépatique
- Bilirubine directe
- Temps de saignement (in vivo)
- Vitamine D 25-OH
- Dosage du (1-3)-β-D-glucane sérique
Sondage portant sur les Rapports - Utilisation judicieuse des analyses biomédicales :
- Fer sérique
- Urée sérique
- T4L
- Électrophorèse des protéines sériques
- Dosage des folates sériques
- Dosage de la vitamine B12
- Test de la vitesse de sédimentation érythrocytaire
- Méthodologie
- Dosage de l'aspartate aminotransférase pour l'investigation d'une atteinte hépatique
- Dosage de la bilirubine directe
- Dosage de la vitamine D 25-OH
- Temps de saignement (in vivo)
- Dosage du (1-3)-β-D-glucane sérique